NICE recommends lenalidomide for treating blood disorders
NICE has issued final draft guidance recommending lenalidomide, an immunomodulatory drug also known as Revlimid, as an option for treating myelodysplastic syndromes (MDS).
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units